Project Grant R01HL186278
Award Date 9/1/26
Completion Date 5/31/30
Dollars Obligated $765K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Minneapolis, MN 55455, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Minnesota $746,979 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mechanisms of pain in sickle cell disease. The research uses transgenic mice with sickle cell disease to study how vaso-occlusive crises trigger severe pain. The project examines the role of lysophosphatidic acid (LPA), a pain mediator elevated during hypoxia-induced vaso-occlusion, and tests...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Minnesota $543,957 on July 6, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how evolving extracellular matrices drive maturation of human pluripotent stem cell-derived cardiomyocytes. The research tests the hypothesis that cardiomyocyte maturation is enhanced through signaling of an evolving extracellular matrix deposited by cardiac fibroblasts in response to dynamic...
- The National Heart, Lung, and Blood Institute awarded Cincinnati Children's Hospital Medical Center $128,589 on September 27, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the contribution of JNK signaling to exercise pressor reflex dysfunction in primary hypertension. The research tests the hypothesis that enhanced JNK signaling in dorsal root ganglia of hypertensive mice occurs through increased peripheral tumor necrosis factor-alpha, resulting in...
- The National Heart, Lung, and Blood Institute awarded the University of Florida $688,383 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 1, 2026, to support preclinical and translational research on mitochondrial efficiency in peripheral artery disease. The project, titled "Enhancing OXPHOS Efficiency to Promote Muscle Function and Regeneration in Peripheral Artery Disease," will develop strategies to optimize leg muscle oxidative metabolism in PAD...
- The National Heart, Lung, and Blood Institute awarded New York University $872,787 on August 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct proteomic discovery and validation research on chronic limb-threatening ischemia (CLTI), the most severe form of peripheral artery disease. The award funds development of proteomic signatures to predict major adverse limb events (MALE) and major adverse cardiovascular events (MACE) in CLTI patients, and to guide...
- The National Heart, Lung, and Blood Institute awarded Research Institute At Nationwide Children's Hospital $1,326,945 on September 10, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a translatable molecular imaging paradigm for comprehensive assessment of peripheral artery disease (PAD). The recipient will characterize stages of peripheral atherosclerosis using dual-phase PET/CT imaging with fluorine-18 sodium fluoride (18F-NAF) to quantify both regional muscle...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Beth Israel Deaconess Medical Center, Inc. $164,484 on August 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of the mechanosensitive ion channel PIEZO1 in thrombotic responses to heterogeneous mechanical forces across distinct vascular beds. The recipient will employ pharmacological and genetic tools to modulate PIEZO1 channels in in vitro mechanical activation...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Minnesota a project grant of $111,795 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research into TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) signaling in atherosclerosis progression. The study will test whether TREM2 blockade using a blocking antibody attenuates atherosclerotic plaque progression by limiting macrophage lipid uptake and...
- The National Heart, Lung, and Blood Institute awarded $657,595 to the Regents of the University of Minnesota on June 22, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop novel statistical methods and computational tools for high-dimensional mediation analysis of cardiovascular disease pathways. The project, supported through NIH's Project Grant mechanism, addresses the challenge of analyzing large-scale molecular datasets, including those from the NHLBI TOPMed...
- The National Heart, Lung, and Blood Institute awarded The Johns Hopkins University $248,919 in a Project Grant (CFDA 93.837, Cardiovascular Diseases Research) on June 1, 2026, to investigate skeletal muscle metabolism and exercise intolerance in heart failure patients with preserved ejection fraction (HFPEF). The award funds research using phosphorus magnetic resonance spectroscopy and magnetic resonance imaging to simultaneously measure muscle metabolism and peripheral blood flow in HFPEF...